Skip to content

A phase 1, randomized, placebo-controlled, double-blind, single center, multiple-dose, parallel trial evaluating the impact of apraglutide on gastric emptying of liquids in healthy subjects

A phase 1, randomized, placebo-controlled, double-blind, single center, multiple-dose, parallel trial evaluating the impact of apraglutide on gastric emptying of liquids in healthy subjects - Multiple-dose trial evaluating impact of apraglutide on gastric emptying

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON53626
Enrollment
36
Registered
2023-02-07
Start date
2023-03-02
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short Bowel Syndrome Short Bowel Syndrome

Interventions

Volunteers will receive an injection of apraglutide two times: once on Day 2 and once on Day 9. The dose that will be given each time is 5 milligram (mg). Paracetamol will be given twice: once on Da

Sponsors

VectivBio AG
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Signed and dated informed consent form (ICF) prior to any trial-mandated procedure 2. Subject must be healthy, as determined by medical history, complete physical examination (including vital signs) and safety laboratory tests (general biochemistry, hematology, urinalysis) including negative tests for human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C 3. Male or female subjects aged from 18 to 45 years inclusive (gastric motility decreases with age) at the time of signing the ICF 4. Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive 5. Women of childbearing potential having undergone bilateral tubal occlusion or with vasectomized partner. To be considered sterilized or infertile, females must have undergone surgical sterilization (bilateral tubectomy, hysterectomy, or bilateral ovariectomy)

Exclusion criteria

Exclusion criteria: 1. Body weight less than 50.0 kg 2. History of clinically significant gastro-intestinal, hepatic, bronchopulmonary, neurological, cardiovascular, endocrine, or allergic disease 3. Any clinically relevant abnormal laboratory test results that are not in line with subject status of healthy subject 4. Allergy or sensitivity to acetaminophen 5. Known hypersensitivity to the investigational medicinal product (IMP), any of their excipients or drugs of the same class

Design outcomes

Primary

MeasureTime frame
To assess the effect of apraglutide on gastric emptying of liquids in healthy subjects, as measured by the PK of acetaminophen mixed with a liquid meal.

Secondary

MeasureTime frame
To assess the safety and tolerability of apraglutide administered to healthy subjects.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)